Institutional Human Ethical Clearance

COVER SHEET

(for attachment to each copy of the protocol form)

Serial No of IHEC Management Office:

Proposal Title:

	Name, Designation	Address	Signature
	æ	Tel & Fax Nos.	
	Qualifications	Email ID	
PI		Department of	
Collaborators	1.	Official Address of collaborators with FAX and email address	Signature of collaborator
	2.		
	3.		

Funding Source:

1.Type of Study : Epidemiological Basic Sciences An	imal studies]		
Clinical: Single center 🗌 Multicentric Beha	avioral			
2. Status of Review: New Review: Revie	evised 🗌			
3. Clinical Trials: Drug /Vaccines/Device/Herbal Remedies :				
i. Does the study involve use of : Drug Devices	Vaccines 🗌			
Indian Systems of Medicine/ Any other NA				
ii. Is it approved and marketed In India UK & Europe	USA			
Other countries, specify				
iii. Does it involve a change in use, dosage, route of administration? NO If yes, whether DCGI's /Any other Regulatory authority's Permission is obtained? NO				
If yes, Date of permission : iv. Is it an Investigational New Drug?	NA			
If yes, IND No:	1 17 1			
a). Investigator's Brochure submitted	NA			
b). In vitro studies data	NA			
c). Preclinical Studies done	NA			
d). Clinical Study is : Phase I Phase II Phase III	Phase I			
e). Are you aware if this study/similar study is being done elswhere ?	NA			
If Yes, attach details				
4. Subject selection: i. Number of Subjects :				
ii. Duration of study : Years months				
iii. Will subjects from both sexes be recruited	YES	NO		
iv. Inclusion / exclusion criteria given	YES	NO		
v. Type of subjects Volunteers Patients				
vi. Vulnerable subjects NONE (Tick the appropriate boxes) pregnant women children elderly fetus illiterate handicapped terminally ill seriously ill mentally challenged economically & socially backward any other				

vii. Special group subjects (Tick the appropriate boxes)		
()		
captives institutionalized employ	yees	students
any other staff forces		
5. Privacy and confidentiality		
i. Study involves - Direct Identifiers		
Indirect Identifiers/coded		
Completely anonymised/ de	linked	
ii. Confidential handling of data by staff	YES	NO
n. Confidential handling of data by staff	1125	NO
6. Use of biological/ hazardous materials	YES	NO
i. Use of fetal tissue or abortus	120	110
ii. Use of organs or body fluids	YES	NO
iii. Use of recombinant/gene therapy		NO
	YES	
If yes, has Department of Biotechnology (DBT) approval for rDNA products been obtained?		
iv. Use of pre-existing/stored/left over samples	YES	NO
v. Collection for banking/future research	YES	NO
vi. Use of ionising radiation/radioisotopes		
If yes, has Bhaba Atomic Research Centre (BARC) approval		
for Radioactive Isotopes been obtained?		
vii. Use of Infectious/biohazardous specimens	YES	NO
viii. Proper disposal of material	YES	NO
ix. Will any sample collected from the patients be sent	YES	NO
abroad ?		
If Yes, justify with details of collaborators		
a) Is the proposal being submitted for clearance from	YES	NO
Health Ministry's Screening Committee (HMSC) for		
International collaboration?		

b) Sample will be sent abroad because (Tick appropriate box): NA					
Facility not available in India					
7. Consent : *Written Oral Audio-visual i. Consent form : (tick the included elements)					
Understandable languageAlternatives to participationStatement that study involves researchConfidentiality of recordsSponsor of studyContact informationPurpose and proceduresStatement that consent is voluntaryRisks & DiscomfortsRight to withdrawBenefitsConsent for future use of biological materialCompensation for participationBenefits if any on future commercializationcompensation for study related injuryeg. genetic basis for drug development					
*If written consent is not obtained, give reasons:					
ii. Who will obtain consent ? PI/Co-PI PI Nurse/Counsellor Research staff Any other Image: Counsellor					
8. Will any advertising be done for recruitment of Subjects ?					
(posters, flyers, brochure, websites – if so kindly attach a copy) 9. Risks & Benefits: i. Is the risk reasonable compared to the anticipated benefits to subjects / community / country?					
ii. Is there physical / social / psychological risk / discomfort? If Yes, Minimal or no risk More than minimum risk High risk					
Iii.Is there a benefit a) to the subject ? Direct Indirect b) Benefit to society					
10. Data Monitoring i. Is there a data & safety monitoring committee/ Board (DSMB)?					
ii. Is there a plan for reporting of adverse events ? If Yes, reporting is done to : Sponsor Ethics Committee					
iii. Is there a plan for interim analysis of data?					
vi. Are there plans for storage and maintenance of all trial database?If Yes, for how long ?					

11. Is there compensation for participation?				
If Yes, Monetary In kind				
Specify amount and type:				
12. Is there compensation for injury?				
If Yes, by Sponsor by Investigator				
by insurance by any other				
company				
13. Do you have conflict of interest?				
(financial/nonfinancial)				
If Yes, specify :				
Checklist for attached documents:				
Protocol form				
Patient information sheet				
Informed Consent form				
Investigator's brochure for recruiting subjects				
Copy of advertisements/Information brochures				
Copy of clinical trial protocol and/or	\square			
questionnaire				
Institutional Animal Ethics Committee clearance				
CPCSEA clearance, if any				
HMSC/DCGI/DBT/BARC clearance if				
obtained				
ooumou				

Detailed information of Project

INTRODUCTION

SUMMARY

OBJECTIVES

METHODS

TIME PLAN

Any other information ;

Selection of Samples Inclusion Criteria: a)

b) Ready to give written consent to be part of the study

Sample number:

Exclusion Criteria:

Annexure 1

PARTICIPANT INFORMATION SHEET (PIS)

Principal Investigator:

Telephone number:

Title of the Study/Project summary/statement describing the aim of study which you will describe to the subject/patient :

You have been invited to take part in a study, which will be helpful in establishing the cause of

If you agree to participate, the expected duration of your stay in laboratory will be about

Prerequisite for the test

All the techniques to be used in the study are non-invasive and safe.

The records of the study will be kept confidential to protect your privacy.

No discomfort or injury is expected at any point of study.

You will be free to withdraw from the study at any stage

Researchers will bear all the costs of the tests.

Your signature on the consent form means that you understand the information given to you about the study. If you sign the form it means that you agree to join the study. You will be provided a copy of this information sheet to keep with records.

For any further information please contact the following: Name of the investigators with working contact numbers

Annexure 2

PATIENT CONSENT FORM

I have been explained the details of the research study entitled in my own language. I have read the patient information sheet carefully and all my queries regarding the study have been answered. I hereby agree, of my own will, to participate in this study.

Date:

Patient's signature:

Patient's name and address :

Witness's signature:

Witness's name ______

Investigator's signature:

Investigator's name and address